However, in recent years, Ozempic and other GLP-1 drugs have been linked to a number of gastrointestinal problems, including gastroparesis, known as stomach paralysis, and bowel obstructions
June 2024: Structure Therapeutics reported positive Phase IIa obesity data for GSBR-1290, an oral non-peptide small-molecule GLP-1 receptor agonist, achieving 6.2% placebo-adjusted mean weight loss at 12 weeks
What clinical trials support twice-weekly tirzepatide dosing for weight loss
Phelan Petty Injury Lawyers is currently reviewing potential cases against the manufacturers of Ozempic and Mounjaro on behalf of people who have developed gastropareses, gallbladder disease, or other severe medical conditions
Neuroprotective Potential Preliminary Research Emerging research indicates Hexarelin may possess neuroprotective properties through mechanisms involving both growth hormone-mediated effects and direct interactions with neural tissue receptors, expanding its research applications beyond cardiovascular and endocrine systems
J Clin Endocrinol Metab (1996) 81(2):4605.10.1210/jcem.81.2.8636250 246 LiuHBravataDMOlkinINayakSRobertsBGarberAMet alSystematic review: the safety and efficacy of growth hormone in the healthy elderly
